Monday, July 28, 2008

Genaera Releases Phase 1 Data And New Preclinical Data On The CNS Function Of Trodusquemine (MSI-1436) At CBI Obesity Summit

“Genaera Corporation (Nasdaq: GENR) announced interim Phase 1 safety and pharmacokinetic (PK) data and new preclinical data on trodusquemine (MSI-1436), Genaera's lead drug candidate for the treatment of type 2 diabetes and obesity, during the CBI 4th Annual Obesity Drug Development Summit in Arlington, Virginia. Dr. Michael McLane, Vice President, Nonclinical Development, presented ‘Trodusquemine: A First-in-Class Allosteric PTP1B Inhibitor for the Treatment of Type 2 Diabetes and Obesity,’ concluding that systemically administered MSI-1436 is well tolerated by type 2 diabetic subjects across its likely range of clinical doses and is functionally active in the hypothalamus, the most important area of the brain for the regulation of food intake, adiposity and glucose homeostasis.”

http://www.medicalnewstoday.com/articles/116210.php

No comments: